CCL

Összesen 3 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM058617
Első szerző:Papp Mária (belgyógyász, gasztroenterológus)
Cím:Rediscovery of the anti-pancreatic antibodies and evaluation of their prognostic value in a prospective clinical cohort of Crohn's patients : the importance of specific target antigens (GP2 and CUZD1) / Maria Papp, Nora Sipeki, Tamas Tornai, Istvan Altorjay, Gary L. Norman, Zakera Shums, Dirk Roggenbuck, Kai Fechner, Winfried Stöcker, Peter Antal-Szalmas, Gabor Veres, Peter Laszlo Lakatos
Dátum:2015
ISSN:1873-9946
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
serologic antibodies
anti-pancreatic antibodies
glycoprotein CUZD1
glycoprotein 2
immunoglobulin A
Crohn's disease
ulcerative colitis
disease progression
Megjelenés:Journal of Crohns & Colitis. - 9 : 8 (2015), p. 659-668. -
További szerzők:Sipeki Nóra (1987-) (általános orvos) Tornai Tamás István (1984-) (belgyógyász) Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Norman, Gary L. Shums, Zakera Roggenbuck, Dirk Fechner, Kai Stocker, Winfried Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Veres Gábor (orvos) Lakatos Péter (Semmelweis Egyetem)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM074575
035-os BibID:(cikkazonosító)1959 (WoS)000442936400001 (Scopus)85068120394
Első szerző:Sowa, Mandy
Cím:Mucosal autoimmunity to cell-bound GP2 isoforms is a sensitive marker in PSC and associated with the clinical phenotype / Mandy Sowa, Rafał Kolenda, Daniel Baumgart, Johann Pratschke, Maria Papp, Tamas Tornai, Jaroslaw Suchanski, Dimitrios Bogdanos, Maria Mytilinaiou, Jutta Hammermann, Martin Laass, Karsten Conrad, Christoph Schramm, Andre Franke, Dirk Roggenbuck, Peter Schierack
Dátum:2018
ISSN:1664-3224
Megjegyzések:Introduction: Zymogen granule glycoprotein 2 (GP2) was demonstrated as first autoimmune mucosal target in primary sclerosing cholangitis (PSC) associated with disease severity. Autoantibodies to four GP2 isoforms (aGP21-4) were found in patients with inflammatory bowel diseases but reactivity against specific GP2 epitopes has not been investigated in PSC yet. Hence, the prevalence of aGP21-4 and their association with the PSC phenotype for risk prediction were examined.Methods: GP2 isoforms were stably expressed as glycosylphosphatidylinositol- anchored molecules in the membrane of HEp-2-cells and used as autoantigenic targets in indirect immunofluorescence assay (IFA). aGP21-4 IgA and IgG were detected by IFA in 212 PSC patients of four European university hospitals and 145 controls comprising 95 patients with cystic fibrosis and 50 healthy subjects.Results: Combined aGP21 and aGP24 IgA testing with a sensitivity of 66.0% and a specificity of 97.9% resulted in the best diagnostic performance (Youden index: 0.64) regarding all aGP2 and combinations thereof. aGP24 IgA positivity is significantly associated with the presence of cirrhosis in PSC (p=0.0056). Logistic regression revealed the occurrence of aGP21 IgA (odds ratio [OR] 1.38, 95% confidence interval [CI]: 1.03-1.86) and aGP24 IgA (OR 1.52, 95%CI: 1.07-2.15) along with male gender (OR 0.51, 95%CI: 0.27-0.97) and older age (OR 1.03 95%CI: 1.01-1.05) as significant risks for the concomitant presence of cirrhosis in PSC.Conclusions: Combined aGP21 and aGP24 IgA analysis is preferred to single aGP2 isoform analysis for sensitive PSC autoantibody testing. Positivity for aGP21 and aGP24 IgA is associated with cirrhosis in PSC and could be used for risk stratification.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
zymogen granule glycoprotein 2
primary sclerosing cholangitis
cirrhosis
cholangiocarcinoma
immunoglobulin A
Megjelenés:Frontiers in Immunology. - 9 (2018), p. 1-10. -
További szerzők:Kolenda, Rafał Baumgart, Daniel Pratschke, Johann Papp Mária (1975-) (belgyógyász, gasztroenterológus) Tornai Tamás István (1984-) (belgyógyász) Suchanski, Jaroslaw Bogdanos, Dimitrios P. Mytilinaiou, Maria Hammermann, Jutta Laass, Martin Conrad, Karsten Schramm, Christoph Franke, Andre Roggenbuck, Dirk Schierack, Peter
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Szerző által megadott URL
Borító:

3.

001-es BibID:BIBFORM071624
035-os BibID:(Cikkazonosító)399 (WOS)000419673100035 (Scopus)85040450338
Első szerző:Tornai Tamás István (belgyógyász)
Cím:Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis / Tornai Tamas, Tornai David, Sipeki Nora, Tornai Istvan, Alsulaimani Rayan, Fechner Kai, Roggenbuck Dirk, Norman Gary L., Veres Gabor, Par Gabriella, Par Alajos, Szalay Ferenc, Lakatos Peter Laszlo, Antal-Szalmas Peter, Papp Maria
Dátum:2018
Megjegyzések:Glycoprotein 2[GP2] is a specific target of pancreatic autoantibodies[PAbs] in Crohn's disease(CD) and is involved in gut innate immunity processes. Our aim was to evaluate the prevalence and prognostic potential of PAbs in primary sclerosing cholangitis(PSC). Sixty-five PSC patients were tested for PAbs by indirect immunofluorescence and compared with healthy (n=100) and chronic liver disease controls(CLD, n=488). Additionally, a panel of anti-microbial antibodies and secretory (s)IgA levels were measured, as markers of bacterial translocation and immune dysregulation. PAbs were more frequent in PSC (46.2%) compared to controls(healthy:0% and CLD:4.5%), P<0.001, for each]. Occurrence of anti-GP2 antibody was 30.8% (20/65) and was exclusively of IgA isotype. Anti-GP2 IgA positive patients had higher sIgA levels (P=0.021). With flow-cytometry, 68.4% (13/19) of anti-GP2 IgA antibodies were bound with secretory component, suggesting an active retro-transportation of anti-GP2 from the gut lumen to the mucosa. Presence of anti-GP2 IgA was associated with shorter transplant-free survival [PLogRank<0.01] during the prospective follow-up (median, IQR: 87 [9-99] months) and remained an independent predictor after adjusting for Mayo risk score (HR: 4.69 [1.05-21.04], P=0.043). These results highlight the significance of gut-liver interactions in PSC. Anti-GP2 IgA might be a valuable tool for risk stratification in PSC and considered as a potential therapeutic target.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
primary sclerosing cholangitis
pancreatic autoantibodies
glycoprotein 2
CUZD1
secretory immunglobulin
gut failure
Megjelenés:Scientific Reports. - 8 : 1 (2018), p. 1-11. -
További szerzők:Tornai Dávid (1989-) (hepatológia, biomarker kutatás) Sipeki Nóra (1987-) (általános orvos) Tornai István (1954-) (belgyógyász, gasztroenterológus) Alsulaimani, Rayan Fechner, Kai Roggenbuck, Dirk Norman, Gary L. Veres Gábor (orvos) Pár Gabriella Pár Alajos Szalay Ferenc (belgyógyász) Lakatos Péter (Semmelweis Egyetem) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Papp Mária (1975-) (belgyógyász, gasztroenterológus)
Pályázati támogatás:OTKA-115818
OTKA
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:
Rekordok letöltése1